필터링

체재

모든

모든
비디오
임상적 특징

정렬

최신

최신
가장 오래된

종양학

Afatinib(지오트립)

/kr/oncology/giotrif/sequencing/giotrif-real-world-practice-sequential-afatinib-followed-osimertinib-feasible

[GIOTRIF] In real-world practice, sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy for EGFR m+ NSCLC patients acquiring T790M during the period of afatinib treatment1

/kr/oncology/giotrif/sequencing/giotrif-based-current-real-world-and-clinical-trial-evidences-optimal-regimen

[GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4-

/kr/oncology/giotrif/efficacy/giotrif-over-1000-published-cases-patients-uncommon-egfr-m-nsclc-treated-giotrif

[GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF®

/kr/oncology/giotrif/efficacy/giotrif-sequential-approach-first-line-giotrif-followed-various-subsequent-treatments-can

[GIOTRIF] A sequential approach of first-line GIOTRIF® followed by various subsequent treatments can be a feasible and appropriate treatment option for patients with EGFR M+ NSCLC from TOAST study

/kr/oncology/giotrif/efficacy/giotrif-real-world-outcomes-first-line-giotrif-patients-non-small-cell-lung-cancer

[GIOTRIF] Real-world Outcomes of First-line GIOTRIF® in Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations in South Korea